277 related articles for article (PubMed ID: 15279071)
1. Elite volunteer athletes of different sport disciplines may have elevated baseline GH levels divorced from unaltered levels of both IGF-I and GH-dependent bone and collagen markers: a study on-the-field.
Sartorio A; Marazzi N; Agosti F; Faglia G; Corradini C; De Palo E; Cella S; Rigamonti A; Muller EE
J Endocrinol Invest; 2004 May; 27(5):410-5. PubMed ID: 15279071
[TBL] [Abstract][Full Text] [Related]
2. A follow-up of GH-dependent biomarkers during a 6-month period of the sporting season of male and female athletes.
Sartorio A; Jubeau M; Agosti F; Marazzi N; Rigamonti A; Müller EE; Maffiuletti NA
J Endocrinol Invest; 2006 Mar; 29(3):237-43. PubMed ID: 16682837
[TBL] [Abstract][Full Text] [Related]
3. Influence of demographic factors and sport type on growth hormone-responsive markers in elite athletes.
Nelson AE; Howe CJ; Nguyen TV; Leung KC; Trout GJ; Seibel MJ; Baxter RC; Handelsman DJ; Kazlauskas R; Ho KK
J Clin Endocrinol Metab; 2006 Nov; 91(11):4424-32. PubMed ID: 16912136
[TBL] [Abstract][Full Text] [Related]
4. The growth hormone/insulin-like growth factor-I axis hormones and bone markers in elite athletes in response to a maximum exercise test.
Ehrnborg C; Lange KH; Dall R; Christiansen JS; Lundberg PA; Baxter RC; Boroujerdi MA; Bengtsson BA; Healey ML; Pentecost C; Longobardi S; Napoli R; Rosén T;
J Clin Endocrinol Metab; 2003 Jan; 88(1):394-401. PubMed ID: 12519882
[TBL] [Abstract][Full Text] [Related]
5. Intra-individual variation of GH-dependent markers in athletes: comparison of population based and individual thresholds for detection of GH abuse in sports.
Kniess A; Ziegler E; Thieme D; Müller RK
J Pharm Biomed Anal; 2013 Oct; 84():201-8. PubMed ID: 23850935
[TBL] [Abstract][Full Text] [Related]
6. Gender-, age-, body composition- and training workload-dependent differences of GH response to a discipline-specific training session in elite athletes: a study on the field.
Sartorio A; Agosti F; Marazzi N; Trecate L; Silvestri G; Lafortuna C; Cappa M; De Palo E; Faglia G; Corradini C; Cella S; Rigamonti A; Müller EE
J Endocrinol Invest; 2004 Feb; 27(2):121-9. PubMed ID: 15129806
[TBL] [Abstract][Full Text] [Related]
7. Combined evaluation of resting IGF1, N-terminal propeptide of type III procollagen and C-terminal cross-linked telopeptide of type I collagen levels might be useful for detecting inappropriate GH administration in female athletes.
Di Luigi L; Rigamonti AE; Agosti F; Mencarelli M; Sgrò P; Marazzi N; Cella SG; Müller EE; Sartorio A
Eur J Endocrinol; 2009 May; 160(5):753-8. PubMed ID: 19258430
[TBL] [Abstract][Full Text] [Related]
8. Effects of 12 months rec-GH therapy on bone and collagen turnover and bone mineral density in GH deficient children with thalassaemia major.
Sartorio A; Conte G; Conti A; Masala A; Alagna S; Rovasio P; Faglia G
J Endocrinol Invest; 2000 Jun; 23(6):356-61. PubMed ID: 10908162
[TBL] [Abstract][Full Text] [Related]
9. Toward the development of a test for growth hormone (GH) abuse: a study of extreme physiological ranges of GH-dependent markers in 813 elite athletes in the postcompetition setting.
Healy ML; Dall R; Gibney J; Bassett E; Ehrnborg C; Pentecost C; Rosen T; Cittadini A; Baxter RC; Sönksen PH
J Clin Endocrinol Metab; 2005 Feb; 90(2):641-9. PubMed ID: 15546908
[TBL] [Abstract][Full Text] [Related]
10. Serum insulin-like growth factor-I and pro-collagen type III N-terminal peptide in adolescent elite athletes: implications for the detection of growth hormone abuse in sport.
Guha N; Erotokritou-Mulligan I; Burford C; Strobridge G; Brigg J; Drake T; Bassett EE; Cowan D; Bartlett C; Sönksen PH; Holt RI
J Clin Endocrinol Metab; 2010 Jun; 95(6):2969-76. PubMed ID: 20410221
[TBL] [Abstract][Full Text] [Related]
11. Immunoassays for the measurement of IGF-II, IGFBP-2 and -3, and ICTP as indirect biomarkers of recombinant human growth hormone misuse in sport. Values in selected population of athletes.
Abellan R; Ventura R; Palmi I; di Carlo S; Bacosi A; Bellver M; Olive R; Pascual JA; Pacifici R; Segura J; Zuccaro P; Pichini S
J Pharm Biomed Anal; 2008 Nov; 48(3):844-52. PubMed ID: 18617352
[TBL] [Abstract][Full Text] [Related]
12. [Effect of GH/IGF-I deficiency on bone and collagen turnover in children and adults with GH deficiency].
Sartorio A; Conti A; Monzani M; Ferrero S; Biella O; Casati G; Faglia G
Minerva Endocrinol; 1995 Jun; 20(2):135-40. PubMed ID: 8531895
[TBL] [Abstract][Full Text] [Related]
13. Dose-dependent effects of recombinant human growth hormone on biochemical markers of bone and collagen metabolism in adult growth hormone deficiency.
Bollerslev J; Møller J; Thomas S; Djøseland O; Christiansen JS
Eur J Endocrinol; 1996 Dec; 135(6):666-71. PubMed ID: 9025710
[TBL] [Abstract][Full Text] [Related]
14. Combined evaluation of resting IGF-I, N-terminal propeptide of type III procollagen (PIIINP) and C-terminal cross-linked telopeptide of type I collagen (ICTP) levels might be useful for detecting inappropriate GH administration in athletes: a preliminary report.
Sartorio A; Agosti F; Marazzi N; Maffiuletti NA; Cella SG; Rigamonti AE; Guidetti L; Di Luigi L; Muller EE
Clin Endocrinol (Oxf); 2004 Oct; 61(4):487-93. PubMed ID: 15473882
[TBL] [Abstract][Full Text] [Related]
15. The development of decision limits for the implementation of the GH-2000 detection methodology using current commercial insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays.
Erotokritou-Mulligan I; Guha N; Stow M; Bassett EE; Bartlett C; Cowan DA; Sönksen PH; Holt RI
Growth Horm IGF Res; 2012 Apr; 22(2):53-8. PubMed ID: 22305721
[TBL] [Abstract][Full Text] [Related]
16. The development of decision limits for the GH-2000 detection methodology using additional insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays.
Holt RI; Böhning W; Guha N; Bartlett C; Cowan DA; Giraud S; Bassett EE; Sönksen PH; Böhning D
Drug Test Anal; 2015 Sep; 7(9):745-55. PubMed ID: 25645199
[TBL] [Abstract][Full Text] [Related]
17. New markers of bone and collagen turnover in children and adults with growth hormone deficiency.
Sartorio A; Conti A; Monzani M
Postgrad Med J; 1993 Nov; 69(817):846-50. PubMed ID: 8290428
[TBL] [Abstract][Full Text] [Related]
18. Biochemical markers of recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes.
Guha N; Erotokritou-Mulligan I; Nevitt SP; Francis M; Bartlett C; Cowan DA; Bassett EE; Sönksen PH; Holt RI
Drug Test Anal; 2013; 5(11-12):843-9. PubMed ID: 24173773
[TBL] [Abstract][Full Text] [Related]
19. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal.
Parkinson C; Kassem M; Heickendorff L; Flyvbjerg A; Trainer PJ
J Clin Endocrinol Metab; 2003 Dec; 88(12):5650-5. PubMed ID: 14671148
[TBL] [Abstract][Full Text] [Related]
20. Long-term monitoring of rec-GH treatment by serial determination of serum aminoterminal propeptide of type III procollagen in children and adults with GH deficiency.
Sartorio A; Arosio M; Conti A; Ferrero S; Porretti S; Faglia G
J Endocrinol Invest; 1999 Mar; 22(3):169-75. PubMed ID: 10219883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
